Literature DB >> 22869713

Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition.

Rainer Wilcken1, GuoZhen Wang, Frank M Boeckler, Alan R Fersht.   

Abstract

Aggregation of destabilized mutants of the tumor suppressor p53 is a major route for its loss of activity. In order to assay drugs that inhibit aggregation of p53, we established the basic kinetics of aggregation of its core domain, using the mutant Y220C that has a mutation-induced, druggable cavity. Aggregation monitored by light scattering followed lag kinetics. Electron microscopy revealed the formation of small aggregates that subsequently grew to larger amorphous aggregates. The kinetics of aggregation produced surprising results: progress curves followed either by the binding of Thioflavin T or the fluorescence of the protein at 340 nm fitted well to simple two-step sequential first-order lag kinetics with rate constants k(1) and k(2) that were independent of protein concentration, and not to classical nucleation-growth. We suggest a mechanism of first-order formation of an aggregation competent state as being rate determining followed by rapid polymerization with the higher order kinetics. By measuring the inhibition kinetics of k(1) and k(2), we resolved that the process with the higher rate constant followed that of the lower. Further, there was only partial inhibition of k(1) and k(2), which showed two parallel pathways of aggregation, one via a state that requires unfolding of the protein and the other of partial unfolding with the ligand still bound. Inhibition kinetics of ligands provides a useful tool for probing an aggregation mechanism.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22869713      PMCID: PMC3427094          DOI: 10.1073/pnas.1211550109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants.

Authors:  Assaf Friedler; Lars O Hansson; Dmitry B Veprintsev; Stefan M V Freund; Thomas M Rippin; Penka V Nikolova; Mark R Proctor; Stefan Rüdiger; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

Review 2.  Rescuing the function of mutant p53.

Authors:  A N Bullock; A R Fersht
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

3.  Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.

Authors:  Jie Xu; Joke Reumers; José R Couceiro; Frederik De Smet; Rodrigo Gallardo; Stanislav Rudyak; Ann Cornelis; Jef Rozenski; Aleksandra Zwolinska; Jean-Christophe Marine; Diether Lambrechts; Young-Ah Suh; Frederic Rousseau; Joost Schymkowitz
Journal:  Nat Chem Biol       Date:  2011-03-27       Impact factor: 15.040

4.  Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.

Authors:  A N Bullock; J Henckel; A R Fersht
Journal:  Oncogene       Date:  2000-03-02       Impact factor: 9.867

5.  Assessing the contribution of heterogeneous distributions of oligomers to aggregation mechanisms of polyglutamine peptides.

Authors:  Andreas Vitalis; Rohit V Pappu
Journal:  Biophys Chem       Date:  2011-04-12       Impact factor: 2.352

6.  Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain.

Authors:  James S Butler; Stewart N Loh
Journal:  Biochemistry       Date:  2003-03-04       Impact factor: 3.162

7.  Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation.

Authors:  Songming Chen; Frank A Ferrone; Ronald Wetzel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-19       Impact factor: 11.205

8.  Structural basis for understanding oncogenic p53 mutations and designing rescue drugs.

Authors:  Andreas C Joerger; Hwee Ching Ang; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-02       Impact factor: 11.205

9.  Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.

Authors:  Ana P D Ano Bom; Luciana P Rangel; Danielly C F Costa; Guilherme A P de Oliveira; Daniel Sanches; Carolina A Braga; Lisandra M Gava; Carlos H I Ramos; Ana O T Cepeda; Ana C Stumbo; Claudia V De Moura Gallo; Yraima Cordeiro; Jerson L Silva
Journal:  J Biol Chem       Date:  2012-06-19       Impact factor: 5.157

10.  First-order rate-determining aggregation mechanism of p53 and its implications.

Authors:  GuoZhen Wang; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-06       Impact factor: 11.205

View more
  51 in total

1.  p53 protein aggregation promotes platinum resistance in ovarian cancer.

Authors:  Y Yang-Hartwich; M G Soteras; Z P Lin; J Holmberg; N Sumi; V Craveiro; M Liang; E Romanoff; J Bingham; F Garofalo; A Alvero; G Mor
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

2.  Self-aggregation and coaggregation of the p53 core fragment with its aggregation gatekeeper variant.

Authors:  Jiangtao Lei; Ruxi Qi; Guanghong Wei; Ruth Nussinov; Buyong Ma
Journal:  Phys Chem Chem Phys       Date:  2016-03-21       Impact factor: 3.676

3.  Wild-type human γD-crystallin promotes aggregation of its oxidation-mimicking, misfolding-prone W42Q mutant.

Authors:  Eugene Serebryany; Jonathan A King
Journal:  J Biol Chem       Date:  2015-03-18       Impact factor: 5.157

4.  Orthogonal high-throughput thermal scanning method for rank ordering protein formulations.

Authors:  Vishal C Nashine; Andrew M Kroetsch; Erinc Sahin; Rong Zhou; Monica L Adams
Journal:  AAPS PharmSciTech       Date:  2013-09-04       Impact factor: 3.246

Review 5.  Salvation of the fallen angel: Reactivating mutant p53.

Authors:  Yang Li; Zhuoyi Wang; Yuchen Chen; Robert B Petersen; Ling Zheng; Kun Huang
Journal:  Br J Pharmacol       Date:  2019-02-28       Impact factor: 8.739

6.  p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.

Authors:  Luciana P Rangel; Giulia D S Ferretti; Caroline L Costa; Sarah M M V Andrade; Renato S Carvalho; Danielly C F Costa; Jerson L Silva
Journal:  J Biol Chem       Date:  2019-01-02       Impact factor: 5.157

7.  A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.

Authors:  Alice Soragni; Deanna M Janzen; Lisa M Johnson; Anne G Lindgren; Anh Thai-Quynh Nguyen; Ekaterina Tiourin; Angela B Soriaga; Jing Lu; Lin Jiang; Kym F Faull; Matteo Pellegrini; Sanaz Memarzadeh; David S Eisenberg
Journal:  Cancer Cell       Date:  2015-12-31       Impact factor: 31.743

Review 8.  Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?

Authors:  Danielly C F Costa; Guilherme A P de Oliveira; Elio A Cino; Iaci N Soares; Luciana P Rangel; Jerson L Silva
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-10-03       Impact factor: 10.005

Review 9.  p53 mutations in cancer.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Nat Cell Biol       Date:  2013-01       Impact factor: 28.824

10.  Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy?

Authors:  Sujata Choudhury; Vamsi K Kolukula; Anju Preet; Chris Albanese; Maria Laura Avantaggiati
Journal:  Cell Cycle       Date:  2013-03-06       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.